AstraZeneca's immunotherapy drug scores key Phase III lung cancer win - MedCity News

AstraZeneca's immunotherapy drug scores key Phase III lung cancer win  MedCity News

The company said the Phase III CASPIAN study of Imfinzi in first-line, extensive-stage small-cell lung cancer was successful, but did not disclose further details.



Comments

Popular posts from this blog

Oncology: The disease, dynamics & challenges of market research

A Review of the Etiology and Epidemiology of Bladder Cancer: All ...

Lung Cancer Among People Who Never Smoked